INTRODUCTION
============

The prevalence of diabetes has increased from 108 million to 422 million over the past three decades. In this pandemic, the low- and middle-income countries (LMICs) experienced the largest surge due to rapidly changing lifestyles and environment \[[@gfy154-B1]\]. Diabetes is the leading cause of end-stage renal disease (ESRD) worldwide. The incidence of diabetes-associated ESRD has been estimated to be 10 times higher than in those without diabetes \[[@gfy154-B2]\]. In both community- and clinic-based settings, albuminuria and estimated glomerular filtration rate (eGFR) are independent predictors of cardiovascular--renal complications and premature death in people with diabetes \[[@gfy154-B3]\].

Chronic kidney disease (CKD) is treatable with intensive risk factor control and the use of renoprotective agents \[[@gfy154-B4], [@gfy154-B5]\]. Professional organizations recommend CKD screening using urinary albumin and eGFR every 6--12 months for early identification and timely intervention \[[@gfy154-B6]\]. However, there are huge regional disparities in the implementation of these recommendations, ranging from 12.6% to 67.9% \[[@gfy154-B7], [@gfy154-B8]\]. Low socio-economic status, limited resources (e.g. funding, facilities and workforce), large patient volume and poor disease awareness in both patients and health care providers are major barriers in improving care, leading to increased morbidity and premature death, especially in LMICs \[[@gfy154-B9], [@gfy154-B10]\].

Sudomotor dysfunction is the earliest manifestation of distal small-fibre neuropathy in type 2 diabetes (T2D) and may aid in CKD screening and detection \[[@gfy154-B11]\]. By placing electrodes on the palms and soles, which are rich in sweat glands, SUDOSCAN evaluates sudomotor (peripheral autonomic) function through measurement of electrochemical skin conductance (ESC) using reverse iontophoresis and chronoamperometry \[[@gfy154-B11]\]. Herein we examine the utility of the method to detect individuals with T2D at risk of developing cardiovascular--renal events in a prospective cohort.

MATERIALS AND METHODS
=====================

Study design and population
---------------------------

[Figure 1](#gfy154-F1){ref-type="fig"} depicts the study flow. The Joint Asia Diabetes Evaluation (JADE) Programme and cross-sectional evaluation of the study have been reported \[[@gfy154-B14], [@gfy154-B15]\]. Briefly, this was a prospective follow-up study involving Chinese adults ≥18 years of age with T2D and free from cardiovascular--renal diseases recruited between 2012 and 2013 from the Diabetes and Endocrine Centre, Prince of Wales Hospital (PWH) and Yao Chung Kit Diabetes Assessment Centre, Chinese University of Hong Kong (CUHK). All participants underwent comprehensive assessment for risk factors and complications, including eye/feet examination and blood/urine tests \[[@gfy154-B14]\], with simultaneous ESC measurement at enrolment. All anonymized data were entered into the web-based JADE portal for analysis \[[@gfy154-B14]\].

![Overview of the study cohort.](gfy154f1){#gfy154-F1}

SUDOSCAN (Impeto Medical, Paris, France), a non-invasive and painless tool, comprises two sets of electrodes for the hands and feet that are connected to a computer for analysis \[[@gfy154-B11], [@gfy154-B16]\]. An incremental low voltage (1--4 V) was applied with left and right electrodes acting as cathode and anode alternately. While the keratinized epidermis is electrically insulated at voltages \<10 V, the sweat glands can transmit electrically charged ions to the electrodes placed on the cutaneous surface (reverse iontophoresis method). The sweat chloride ion current, which is reported as the ESC (microSiemens, µS), reflects the C fibre innervation and function of the sweat glands \[[@gfy154-B11]\]. Collectively, this technology provides rapid (2--3 min) and precise ESC measurements of the hands and feet, of which the mean global skin conductance is calculated as 0.5 × \[(right + left hand)/2 + (right + left foot)/2\] \[[@gfy154-B11], [@gfy154-B16]\]. The hands/feet ESC measurements and participant's age are incorporated into a proprietary built-in algorithm to calculate the ESC composite score, which ranges from 0 to 150. Compared with the ESC composite score of ≤60 for sudomotor dysfunction defined by the manufacturer, ethnic-specific thresholds for CKD screening have been reported, such as a composite score ≤53 or ≤55 for Hong Kong Chinese and \<59.5 for mainland Chinese \[[@gfy154-B15], [@gfy154-B17], [@gfy154-B18]\] or a mean feet ESC measurement ≤37.6 for African Americans and ≤44.4 for European Americans \[[@gfy154-B13]\].

All participants were referred from community-/hospital-based clinics operated by the Hospital Authority, which used a territory-wide clinical management system that captured all laboratory, hospitalization and drug data. The majority of participants were followed up in the medical clinics at intervals of 3--4 months with measurement of renal function every 6--12 months. Serum creatinine was measured by the isotope dilution mass spectroscopy--traceable Jaffe kinetic method (Dade Behring, Deerfield, IL, USA). We estimated GFR using the Chronic Kidney Disease Epidemiology Collaboration creatinine equation \[[@gfy154-B19]\]. All assays were performed by the Department of Clinical Pathology at PWH with external accreditation.

All hospital discharges were coded according to the *International Classification of Diseases, Ninth Revision*. The code listed as principal diagnosis was used for outcome definition with data censored on 31 May 2015 ([Supplementary data](#sup1){ref-type="supplementary-material"}, [Table S1](#sup1){ref-type="supplementary-material"}). The primary outcomes were incident CKD (defined as eGFR \<60 ml/min/1.73 m^2^, need for renal replacement therapy or death from renal causes) and cardiovascular disease (CVD; defined as any new-onset fatal/non-fatal coronary heart disease, stroke or peripheral vascular disease) ([Supplementary data](#sup1){ref-type="supplementary-material"}, [Tables S1--S2](#sup1){ref-type="supplementary-material"}). We defined CKD using the last available eGFR in 6 months before and after the censor date, whereby the measurement closest to the censor date was selected \[[@gfy154-B20]\]. The exploratory outcome was all-cause death. This study was approved by the local institutional review board. All participants provided written informed consent.

###### 

Clinical characteristics of participants without prevalent cardiovascular--renal diseases at baseline, stratified by baseline ESC composite score ≤53 or \>53

  Characteristics                                 All (*n* = 2028)   ESC composite score ≤53 (*n* = 574)   ESC composite score \>53 (*n* = 1454)   P-value                                    
  ----------------------------------------------- ------------------ ------------------------------------- --------------------------------------- ----------------- ------ ----------------- ---------
  At baseline                                                                                                                                                                                 
  Demographic data                                                                                                                                                                            
   Age (years)                                    2028               57.0 (10.0)                           574                                     66.8 (6.5)        1454   53.1 (8.4)        \<0.001
   Men, *n* (%)                                   2028               1137 (56.1)                           574                                     297 (51.7)        1454   840 (57.8)        0.014
   Smoking history                                2027                                                     574                                                       1453                     \<0.001
    Current smoker, *n* (%)                                          231 (11.4)                                                                    42 (7.3)                 189 (13.0)        
    Ex-smoker, *n* (%)                                               327 (16.1)                                                                    130 (22.6)               197 (13.6)        
    Never smoker, *n* (%)                                            1469 (72.5)                                                                   402 (70.0)               1067 (73.4)       
   Duration of diabetes (years), median (IQR)     1955               7.0 (3.0--13.0)                       573                                     9.0 (5.0--16.0)   1382   6.0 (3.0--12.0)   \<0.001
   Duration of follow-up (years)                  2028               2.3 (0.4)                             574                                     2.4 (0.4)         1454   2.3 (0.4)         0.245
  Cardiometabolic risk factors                                                                                                                                                                
   HbA1c, NGSP (%)                                2028               7.5 (1.4)                             574                                     7.3 (1.3)         1454   7.5 (1.5)         0.008
   SBP (mmHg)                                     2028               130.8 (16.5)                          574                                     135.4 (17.0)      1454   128.9 (15.9)      \<0.001
   Diastolic blood pressure (mmHg)                2028               78.3 (9.8)                            574                                     77.1 (9.8)        1454   78.8 (9.8)        \<0.001
   Total cholesterol (mmol/L)                     1982               4.5 (0.9)                             561                                     4.3 (0.8)         1421   4.5 (0.9)         \<0.001
   LDL cholesterol (mmol/L)                       2007               2.4 (0.8)                             569                                     2.3 (0.8)         1438   2.5 (0.8)         \<0.001
   HDL cholesterol (mmol/L)                       2027               1.3 (0.4)                             573                                     1.4 (0.4)         1454   1.3 (0.4)         0.015
    Men                                           1136               1.3 (0.3)                             296                                     1.3 (0.4)         840    1.2 (0.3)         0.025
    Women                                         891                1.4 (0.4)                             277                                     1.5 (0.4)         614    1.4 (0.4)         0.655
   Triglyceride (mmol/L), median (IQR)            2028               1.2 (0.9--1.8)                        574                                     1.2 (0.9--1.6)    1454   1.2 (0.9--1.8)    0.007
   Body mass index (kg/m^2^)                      2028               25.9 (4.2)                            574                                     24.9 (3.6)        1454   26.3 (4.4)        \<0.001
   Waist circumference (cm)                       2028               90.0 (10.8)                           574                                     88.7 (10.0)       1454   90.6 (11.1)       \<0.001
    Men                                           1137               92.1 (10.1)                           297                                     90.7 (9.8)        840    92.7 (10.1)       0.003
    Women                                         891                87.3 (11.2)                           277                                     86.5 (9.7)        614    87.7 (11.7)       0.104
   eGFR (mL/min/1.73 m^2^)                        2028               94.0 (13.7)                           574                                     85.3 (12.1)       1454   97.4 (12.8)       \<0.001
   Urinary ACR (mg/mmol), median (IQR)            2024               1.1 (0.5--3.3)                        573                                     1.3 (0.6--4.2)    1451   1.0 (0.5--3.1)    0.001
  Complications at baseline                                                                                                                                                                   
   Sensory neuropathy, *n* (%)                    2028               39 (1.9)                              574                                     19 (3.3)          1454   20 (1.4)          0.004
   Diabetic retinopathy, *n* (%)                  2027               366 (18.1)                            573                                     128 (22.3)        1454   238 (16.4)        0.002
   Albuminuria                                    2024                                                     573                                                       1451                     0.075
    \<3 mg/mmol, *n* (%)                                             1486 (73.4)                                                                   403 (70.3)               1083 (74.6)       
    3--30 mg/mmol, *n* (%)                                           438 (21.6)                                                                    143 (25.0)               295 (20.3)        
    ≥30 mg/mmol, *n* (%)                                             100 (4.9)                                                                     27 (4.7)                 73 (5.0)          
  Medication use                                                                                                                                                                              
   Oral glucose-lowering agents, *n* (%)          2028               1741 (85.8)                           574                                     498 (86.8)        1454   1243 (85.5)       0.459
   Insulin, *n* (%)                               2028               391 (19.3)                            574                                     107 (18.6)        1454   284 (19.5)        0.647
   RAS inhibitors, *n* (%)                        2028               833 (41.1)                            574                                     279 (48.6)        1454   554 (38.1)        \<0.001
   Statins, *n* (%)                               2028               973 (48.0)                            574                                     317 (55.2)        1454   656 (45.1)        \<0.001
  ESC measurements (µS)                                                                                                                                                                       
   Mean global ESC                                2028               59.4 (18.5)                           574                                     46.4 (18.3)       1454   64.5 (15.9)       \<0.001
   Hands ESC                                      2027               55.6 (20.6)                           574                                     43.5 (21.7)       1453   60.3 (18.1)       \<0.001
   Feet ESC                                       2028               63.0 (18.0)                           574                                     49.4 (18.4)       1454   68.5 (14.7)       \<0.001
   ESC composite score                            2028               60.7 (14.5)                           574                                     44.2 (7.3)        1454   67.2 (11.1)       \<0.001
  Incidence of events at 2.3 years of follow-up                                                                                                                                               
   CVD, *n* (%)                                   2028               25 (1.2)                              574                                     13 (2.3)          1454   12 (0.8)          0.008
   CKD, *n* (%)                                   2028               163 (8.0)                             574                                     98 (17.1)         1454   65 (4.5)          \<0.001
   ESRD, *n* (%)                                  2028               4 (0.2)                               574                                     1 (0.2)           1454   3 (0.2)           1.000
   All-cause death, *n* (%)                       2028               15 (0.7)                              574                                     7 (1.2)           1454   8 (0.6)           0.147

Data are expressed as mean (SD) unless stated otherwise. eGFR was calculated from the Chronic Kidney Disease Epidemiology Collaboration equation. CVD is defined as the presence of any coronary heart disease, stroke or peripheral vascular disease. The mean global ESC was calculated using 0.5 × \[(right + left hand ESC/2) + (right + left foot ESC/2)\].

ESRD, end-stage renal disease; HDL, high-density lipoprotein; NGSP, National Glycohemoglobin Standardization Program.

###### 

Cox proportional hazards models of baseline ESC composite score and risk of incident cardiovascular--renal events and all-cause death (including participants without prevalent cardiovascular--renal diseases at baseline)

                                                           Incident CKD                                                                                                           
  -------------------------------------------------------- -------------- ------------------- --------- ----------- ------------------- --------- ----------- ------------------- -------
  ESC composite score[^a^](#tblfn3){ref-type="table-fn"}   163 (8.0)      1.06 (1.05--1.07)   \<0.001   162 (8.3)   1.06 (1.05--1.07)   \<0.001   158 (8.2)   1.02 (1.01--1.04)   0.001
  ESC composite score[^b^](#tblfn4){ref-type="table-fn"}                                                                                                                          
   Score ≤53 versus \>53                                   163 (8.0)      4.06 (2.97--5.55)   \<0.001   162 (8.3)   3.60 (2.61--4.97)   \<0.001   158 (8.2)   1.56 (1.09--2.23)   0.015
   Score ≤55 versus \>55                                   163 (8.0)      3.74 (2.72--5.16)   \<0.001   162 (8.3)   3.35 (2.41--4.65)   \<0.001   158 (8.2)   1.49 (1.04--2.14)   0.029
   Score ≤60 versus \>60                                   163 (8.0)      4.07 (2.80--5.92)   \<0.001   162 (8.3)   3.60 (2.45--5.28)   \<0.001   158 (8.2)   1.38 (0.92--2.07)   0.118
  Mean global ESC                                          163 (8.0)      1.02 (1.01--1.03)   \<0.001   162 (8.3)   1.01 (1.00--1.02)   0.004     158 (8.2)   1.01 (1.00--1.02)   0.024
  Hands ESC                                                163 (8.0)      1.02 (1.01--1.03)   \<0.001   162 (8.3)   1.01 (1.00--1.02)   0.004     158 (8.2)   1.01 (1.00--1.02)   0.037
  Feet ESC                                                 163 (8.0)      1.02 (1.01--1.03)   \<0.001   162 (8.3)   1.01 (1.00--1.02)   0.017     158 (8.2)   1.01 (1.00--1.02)   0.040

                                                           Incident CVD                                                                                                     
  -------------------------------------------------------- -------------- ------------------- ------- ---------- ------------------- ------- ---------- ------------------- -------
  ESC composite score[^a^](#tblfn3){ref-type="table-fn"}   25 (1.2)       1.03 (1.00--1.06)   0.032   25 (1.3)   1.03 (1.00--1.06)   0.061   25 (1.3)   1.04 (1.00--1.07)   0.030
  ESC composite score[^b^](#tblfn4){ref-type="table-fn"}                                                                                                                    
   Score ≤53 versus \>53                                   25 (1.2)       2.73 (1.25--5.99)   0.012   25 (1.3)   2.65 (1.19--5.93)   0.018   25 (1.3)   3.11 (1.27--7.62)   0.013
   Score ≤55 versus \>55                                   25 (1.2)       2.94 (1.32--6.54)   0.008   25 (1.3)   2.91 (1.29--6.58)   0.010   25 (1.3)   3.42 (1.39--8.38)   0.007
   Score ≤60 versus \>60                                   25 (1.2)       2.25 (0.97--5.22)   0.058   25 (1.3)   2.14 (0.91--5.04)   0.082   25 (1.3)   2.33 (0.90--6.02)   0.080
  Mean global ESC                                          25 (1.2)       1.01 (0.99--1.03)   0.473   25 (1.3)   1.01 (0.98--1.03)   0.637   25 (1.3)   1.00 (0.98--1.03)   0.700
  Hands ESC                                                25 (1.2)       1.01 (0.99--1.02)   0.621   25 (1.3)   1.00 (0.98--1.02)   0.742   25 (1.3)   1.00 (0.98--1.02)   0.722
  Feet ESC                                                 25 (1.2)       1.01 (0.99--1.03)   0.406   25 (1.3)   1.01 (0.99--1.03)   0.606   25 (1.3)   1.00 (0.98--1.02)   0.735

                                                           All-cause death                                                                                                      
  -------------------------------------------------------- ----------------- ------------------- ------- ---------- ------------------- ------- ---------- -------------------- -------
  ESC composite score[^a^](#tblfn3){ref-type="table-fn"}   15 (0.7)          1.03 (0.99--1.06)   0.167   14 (0.7)   1.04 (1.00--1.08)   0.045   13 (0.7)   1.04 (1.00--1.09)    0.067
  ESC composite score[^b^](#tblfn4){ref-type="table-fn"}                                                                                                                        
   Score ≤53 versus \>53                                   15 (0.7)          2.18 (0.79--6.00)   0.133   14 (0.7)   2.60 (0.89--7.56)   0.080   13 (0.7)   3.53 (0.99--12.49)   0.050
   Score ≤55 versus \>55                                   15 (0.7)          2.20 (0.80--6.08)   0.127   14 (0.7)   2.69 (0.92--7.89)   0.072   13 (0.7)   3.89 (1.09--13.90)   0.036
   Score ≤60 versus \>60                                   15 (0.7)          2.09 (0.72--6.12)   0.178   14 (0.7)   2.68 (0.83--8.69)   0.101   13 (0.7)   2.56 (0.70--9.39)    0.158
  Mean global ESC                                          15 (0.7)          1.00 (0.97--1.03)   0.870   14 (0.7)   1.00 (0.97--1.02)   0.754   13 (0.7)   0.99 (0.96--1.02)    0.646
  Hands ESC                                                15 (0.7)          1.01 (0.98--1.03)   0.530   14 (0.7)   1.00 (0.98--1.03)   0.925   13 (0.7)   1.00 (0.97--1.03)    0.956
  Feet ESC                                                 15 (0.7)          0.99 (0.96--1.02)   0.672   14 (0.7)   0.99 (0.96--1.02)   0.453   13 (0.7)   0.98 (0.95--1.02)    0.318

Continuous variable.

Categorical variable. The HR represents the relative change in the hazard function per 1-unit decrease in the independent variable. The mean global ESC was calculated using 0.5 ×  \[(right + left hand ESC)/2 + (right + left foot)/2\].

Model 1: unadjusted.

Model 2: adjusted for sex, duration of T2D (when either mean global, hands or feet ESC was used as the independent variable, age was added in the model).

Model 3: model 2 plus HbA1c, SBP, LDL cholesterol, logarithmically transformed triglyceride, waist circumference, baseline eGFR, logarithmically transformed urinary ACR, smoking status and use of RAS inhibitors, statins, oral glucose-lowering agents or insulin.

Statistical analysis
--------------------

All data are expressed as mean \[standard deviation (SD)\], median \[interquartile range (IQR)\] and number (percentage), as appropriate. Triglyceride and urinary albumin:creatinine ratio (ACR) were logarithmically transformed. Categorical variables were compared using either χ^2^ or Fisher's exact test and continuous variables with either independent *t* or Mann--Whitney test. Cox regression analyses were performed to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) for clinical events with either the ESC composite score or individual ESC measurements as the independent variable. The covariables for adjustment included sex, duration of diabetes, haemoglobin A1c, systolic blood pressure (SBP), low-density lipoprotein (LDL) cholesterol, triglyceride, waist circumference, baseline eGFR, ACR, smoking and drug usage \[oral glucose-lowering agents, insulin, renin--angiotensin system (RAS) inhibitors and statins\]. There was collinearity between age and ESC composite score (Pearson correlation −0.837) but not with individual ESC measurements.

Subgroup analyses were stratified by pre-defined thresholds of ESC composite score, individual ESC measurements, eGFR \>80 mL/min/1.73 m^2^ and/or albuminuria status (\<3 or \<30 mg/mmol) and annual eGFR decline calculated using a linear mixed-effects model with ≥3 eGFR measurements \[[@gfy154-B21]\]. In the current Kaplan--Meier analysis, which included 2028 participants recruited in the previous study, ESC composite scores ≤53 versus \>53 were used to estimate the survival rate of participants with incident CKD. Taking into account the presence of competing risk of mortality, we performed cumulative incidence functions and subdistribution hazard models to estimate the incidence of cardiovascular--renal events \[[@gfy154-B22], [@gfy154-B23]\].

We assessed the predictive discrimination of the ESC composite score for 3-year risk of all outcomes using the receiver operating characteristics (ROC) area under the curve \[AUC; ranging from 0.5 (no discrimination) to 1.0 (perfect discrimination)\] \[[@gfy154-B24]\], integrated discrimination improvement (IDI; quantification of predicted probabilities of events and non-events based on inclusion of the ESC composite score in the model) and net reclassification improvement (NRI; the probability that patients are appropriately classified into high and low risk) \[[@gfy154-B25], [@gfy154-B26]\]. Two prediction models were used: basic clinical variables (sex and duration of diabetes) and both clinical variables and composite score. An NRI \<0.2, ∼0.4 and \>0.6 is considered weak, intermediate and strong, respectively \[[@gfy154-B27]\]. All statistical analyses were conducted using R software version 3.4.2 (R Project for Statistical Computing, Vienna, Austria) \[[@gfy154-B28]\]. A two-sided P-value \<0.05 denotes statistical significance.

RESULTS
=======

Baseline characteristics
------------------------

During a mean follow-up of 2.3 years, 2028 (71.6%) participants were prospectively monitored for clinical events. The mean age of the cohort was 57.0 (SD 10.0) years, 56.1% were men and the median duration of T2D was 7.0 (IQR 3.0--13.0) years. The mean baseline ESC composite score was 60.7 (SD 14.5). One in four participants had albuminuria and more than 40% were treated with either RAS inhibitors or statins. Participants with an ESC composite score ≤53 were older, had longer disease duration, had higher rates of microvascular complications and were more likely to be on organ-protective agents than those with a score \>53 ([Table 1](#gfy154-T1){ref-type="table"}). Compared with participants without CKD, those with CKD were older, had longer disease duration and a more adverse clinical profile, including obesity with increased medication use, and had a lower ESC composite score ([Supplementary data](#sup1){ref-type="supplementary-material"}, [Tables S3--S4](#sup1){ref-type="supplementary-material"}).

###### 

Comparison of Cox proportional and subdistribution hazards models for incident cardiovascular--renal events (*n* = 1934)

                                                           Cox proportional hazards model, HR (95% CI)   Subdistribution hazard model, SHR (95% CI)                                                                               
  -------------------------------------------------------- --------------------------------------------- -------------------------------------------- ------------------- ------- ------------------- ------- ------------------- -------
  ESC composite score[^a^](#tblfn8){ref-type="table-fn"}   1.02 (1.01--1.04)                             0.001                                        1.04 (1.00--1.07)   0.030   1.02 (1.01--1.04)   0.002   1.04 (1.00--1.07)   0.033
  ESC composite score[^b^](#tblfn9){ref-type="table-fn"}                                                                                                                                                                          
   Score ≤53 versus \>53                                   1.56 (1.09--2.23)                             0.015                                        3.11 (1.27--7.62)   0.013   1.57 (1.09--2.24)   0.014   3.09 (1.42--6.69)   0.004
   Score ≤55 versus \>55                                   1.49 (1.04--2.14)                             0.029                                        3.42 (1.39--8.38)   0.007   1.50 (1.04--2.16)   0.028   3.40 (1.49--7.74)   0.004
   Score ≤60 versus \>60                                   1.38 (0.92--2.07)                             0.118                                        2.33 (0.90--6.02)   0.080   1.37 (0.92--2.04)   0.117   2.32 (1.04--5.14)   0.039
  Mean global ESC                                          1.01 (1.00--1.02)                             0.024                                        1.00 (0.98--1.03)   0.700   1.01 (1.00--1.02)   0.024   1.00 (0.99--1.02)   0.635
  Hands ESC                                                1.01 (1.00--1.02)                             0.037                                        1.00 (0.98--1.02)   0.722   1.01 (1.00--1.02)   0.044   1.00 (0.98--1.02)   0.724
  Feet ESC                                                 1.01 (1.00--1.02)                             0.040                                        1.00 (0.98--1.02)   0.735   1.01 (1.00--1.02)   0.039   1.00 (0.99--1.02)   0.642

Continuous variable.

Categorical variable. Each cell illustrates the hazard per 1-unit decrease of the given independent variable, with different interpretations in both models. For each outcome, the HR represents the relative change in the hazard function in the Cox proportional hazards model. The SHR represents the relative incidence in the subdistribution hazard model. The mean global ESC was calculated using 0.5 ×  \[(right + left hand ESC)/2 + (right + left foot)/2\].

Models were adjusted for sex, duration of T2D, HbA1c, SBP, LDL cholesterol, logarithmically transformed triglyceride, waist circumference, baseline eGFR, logarithmically transformed urinary ACR, smoking status and the use of RAS inhibitors, statins, oral glucose-lowering agents or insulin (when either mean global, hands or feet ESC was used as the independent variable, age was added in the model).

SHR, subdistribution HR.

###### 

The ROC curve, IDI and NRI of the use of ESC composite score in addition to clinical variables in predicting the 3-year risk of cardiovascular--renal diseases and all-cause death

                                        C-index (95% CI)    Absolute IDI (95% CI)   NRI (95% CI)         
  ------------------------------------- ------------------- ----------------------- -------------------- ---------------------
  CKD                                                                                                    
   ESC composite score (continuous)     0.63 (0.59--0.67)   0.74 (0.70--0.78)       0.08 (0.04--0.11)    0.29 (0.14--0.41)
   ESC composite score (53 cut-point)   0.72 (0.68--0.76)   0.05 (0.02--0.08)       0.32 (0.16--0.44)    
  CVD                                                                                                    
   ESC composite score (continuous)     0.65 (0.56--0.75)   0.70 (0.59--0.80)       0.003 (0.00--0.02)   0.22 (−0.12--0.42)
   ESC composite score (53 cut-point)   0.72 (0.63--0.81)   0.004 (0.00--0.03)      0.24 (0.00--0.47)    
  All-cause death                                                                                        
   ESC composite score (continuous)     0.58 (0.41--0.74)   0.67 (0.50--0.85)       0.002 (0.00--0.05)   −0.15 (−0.35--0.25)
   ESC composite score (53 cut-point)   0.66 (0.50--0.82)   0.001 (0.00--0.02)      0.03 (−0.19--0.35)   

Model 1: sex, duration of T2D.

Model 2: model 1 plus ESC composite score.

Clinical outcomes
-----------------

[Table 2](#gfy154-T2){ref-type="table"} shows the relationship between the ESC composite score and the incidence of cardiovascular--renal events and all-cause death. During this observation period, 163 (8.0%) and 25 (1.2%) of the participants developed incident CKD and CVD, respectively. The ESC composite score independently predicted incident CKD, with every unit decrease associated with a 6% increased risk \[HR 1.06 (CI 1.05--1.07)\]. This risk was attenuated to 2% after adjustment for baseline cardiometabolic risk factors, renal function and use of organ-protective agents \[adjusted HR (aHR) 1.02 (95% CI 1.01--1.04)\], albeit still significant. Individual ESC measurements were associated with excess risk of incident CKD, but their predictive power was less robust than the ESC composite score (1% versus 2%).

When we stratified the ESC composite score using the three previously reported thresholds, that is, 53, 55 and 60 (15, 18), only the first two thresholds independently predicted incident CKD in our Chinese cohort. Compared with those with a composite score \>53, participants with a score ≤53 had an aHR of 1.56 (95% CI 1.09--2.23) for CKD. The corresponding aHR for a score ≤55 was 1.49 (95% CI 1.04--2.14).

Every unit decrease in the ESC composite score was associated with a 3% excess risk of incident CVD \[HR 1.03 (95% CI 1.00--1.06)\]. The effect size increased to 4% when adjusted for clinical covariates \[aHR 1.04 (95% CI 1.00--1.07)\]. Participants with an ESC composite score ≤53 or ≤55 had an increased aHR of 3.11 (95% CI 1.27--7.62) and 3.42 (95% CI 1.39--8.38), respectively, for incident CVD, but the association with individual ESC measurements was not significant. Consistent results for incident cardiovascular--renal events were confirmed in the presence of a competing risk of mortality ([Table 3](#gfy154-T3){ref-type="table"}). [Figure 2](#gfy154-F2){ref-type="fig"} and [Supplementary data, Figure S1](#sup1){ref-type="supplementary-material"} show the Kaplan--Meier curve and cumulative incidence of cardiovascular--renal events in participants with an ESC composite score ≤53 and \>53, respectively.

![Kaplan--Meier curve of incident CKD (eGFR \<60 ml/min/1.73 m^2^, need for renal replacement therapy or death from renal causes), stratified by baseline ESC composite score ≤53 (lower line) and \>53 (upper line).](gfy154f2){#gfy154-F2}

[Table 2](#gfy154-T2){ref-type="table"} shows the time-to-event analysis of all-cause death, with a total event rate of 15 (0.7%), with the ESC composite score being an independent predictor, adjusted for sex and disease duration \[aHR 1.04 (95% CI 1.00--1.08)\]. Participants with a composite score ≤55 had an aHR of 3.89 (95% CI 1.09--13.90) compared with those with a high score. When we analysed participants with an ACR \<30 mg/mmol and/or baseline eGFR ≥80 mL/min/1.73 m^2^, a low ESC composite score remained an independent predictor of incident cardiovascular--renal events, albeit its relationship with all-cause death was negated due to fewer events ([Supplementary data](#sup1){ref-type="supplementary-material"}, [Tables S5--S8](#sup1){ref-type="supplementary-material"}). In the whole cohort, every unit decrease in the composite score was also independently associated with faster eGFR decline \[β −0.005 (standard error 0.002), P* *=* *0.048\] ([Supplementary data](#sup1){ref-type="supplementary-material"}, [Table S9](#sup1){ref-type="supplementary-material"}).

[Table 4](#gfy154-T4){ref-type="table"} shows the discrimination and reclassification analyses that assessed the use of the ESC composite score in predicting the 3-year risk of cardiovascular--renal events and all-cause death. For the basic model (sex and duration of diabetes), the AUC was 0.63 (95% CI 0.59--0.67) for CKD, which increased to 0.74 (95% CI 0.70--0.78) with an estimated NRI of 0.29 (95% CI 0.14--0.41) and an absolute IDI change \<1% after addition of the ESC composite score. There was a similar trend for CVD and death, but the ESC composite score did not improve their reclassifications.

DISCUSSION
==========

In Chinese patients with T2D, one-third of the participants had cardiovascular--renal diseases at enrolment to the JADE register. Among those without prevalent cardiovascular--renal diseases, a low ESC composite score independently increased the HR by 1.5--4 for incident cardiovascular--renal events and all-cause death compared with those with a score \>53 or \>55 after 2 years of follow-up. Only 28% of the cohort had a low ESC composite score ≤53, but 60% developed CKD. In contrast, 72% of participants had a high ESC composite score \>53 and only 40% developed CKD. Low individual ESC measurements also predicted a higher incidence of CKD. After adjusting for sex and disease duration, the ESC composite score remained robust in discriminating all outcomes and reclassifying CKD risk. Taken together, SUDOSCAN can be a useful non-invasive tool to identify high-risk individuals for cardiovascular--renal diseases for definitive evaluation and intervention.

SUDOSCAN is an approved technology for measuring autonomic nerve function \[[@gfy154-B16]\]. Autonomic and somatic nerve dysfunctions measured by different methods have been shown to predict poor cardiometabolic outcomes and death in the diabetic population \[[@gfy154-B29]\]. However, use of these measurements in clinical practice (e.g. Michigan Neuropathy Screening Instrument, Utah Early Neuropathy Scale, nerve conduction studies and intraepidermal nerve fibre density) is limited by their subjective nature or technical challenges requiring special staff training \[[@gfy154-B11], [@gfy154-B32]\]. SUDOSCAN has been shown to correlate well with these clinical instruments for evaluation of nerve dysfunction \[[@gfy154-B33], [@gfy154-B34]\]. In this analysis, we further confirmed the utility of SUDOSCAN to measure sudomotor dysfunction for detecting individuals at risk of developing cardiovascular--renal complications. Given its user friendliness and non-invasive nature, the use of this technology might help prioritize screening and intervention strategies, especially in cost-restrained settings.

Globally, 500 million adults ≥20 years of age are suffering from CKD, 80% of whom are living in LMICs \[[@gfy154-B35]\], where only one-third of affected individuals were diagnosed \[[@gfy154-B2]\]. The Global Burden of Disease 2016 Study reported a 30% increase in the death rates attributable to diabetic kidney disease, totalling 500 800 deaths worldwide in the past decade \[[@gfy154-B36]\], although this estimate was likely to be conservative. Hong Kong has a highly subsidized health care system. Since 2000, a team-based structured diabetes assessment and management programme has been progressively introduced in public health care institutions, with a demonstrable decline in the incidence of cardiovascular--renal complications and death. Despite this, the burden of ESRD has remained high, with a crude incidence of 22.5 per 1000 person-years, especially in people with ≥15 years of diabetes, pointing to a need for earlier detection to enable more aggressive management during the early stages of disease \[[@gfy154-B37]\].

Diabetic kidney disease is treatable if detected early and treated intensively \[[@gfy154-B4], [@gfy154-B5]\]. In the UK Prospective Diabetes Study, the annual progression to microalbuminuria was 2% and from microalbuminuria to overt proteinuria was 2.8%, meaning that one in four patients with T2D might develop either microalbuminuria or worsening nephropathy within 10 years of diagnosis \[[@gfy154-B38]\]. Universal screening for CKD provides opportunities to implement preventive strategies to arrest or slow disease progression. However, one in three patients with T2D in LMICs failed to receive routine CKD screening \[[@gfy154-B8]\]. Even in high-income nations such as the UK, a National Diabetes Audit showed a sustained reduction in regular microalbuminuria screening from 84.4% (2013--14) to 65.2% (2016--17) \[[@gfy154-B39]\]. Factors pertaining to the health care system (infrastructure support, access to and high cost of *in vitro* diagnostic tests), health care providers (inefficient communication, lack of trained personnel and ongoing support) and patients (sociodemographic disparities and poor awareness) are common obstacles in optimizing care \[[@gfy154-B8], [@gfy154-B10]\]. In a multinational survey involving 75 058 individuals screened for non-communicable diseases in LMICs, \>90% of affected individuals were unaware of CKD \[[@gfy154-B9]\]. Among those who were aware of CKD, fewer than half had intervention for CKD, which would progress silently to ESRD with poor quality of life and increased socio-economic burden \[[@gfy154-B9]\].

Diagnosis of asymptomatic early-stage CKD, which accounts for 80--90% of all cases, requires measurement of urinary albumin and GFR \[[@gfy154-B2]\]. Although GFR is generally estimated from serum creatinine and/or cystatin, these renal parameters are often not measured in audit reports \[[@gfy154-B8], [@gfy154-B40]\]. The large inter-individual and day-to-day variability of microalbuminuria also has limited predictive value in identifying patients with prevalent CKD or those who are at risk of developing CKD \[[@gfy154-B41]\]. With increasing usage of RAS inhibitors and better risk factor control, remission of microalbuminuria has been reported in 20--60% of individuals with diabetes. Of note, individuals with normoalbuminuria and reduced GFR could also have poor clinical outcomes \[[@gfy154-B41]\]. In this light, diabetic kidney disease is a heterogeneous condition, with normoalbuminuria *per se* being associated with structural kidney damage where 20--40% of these individuals might continue to progress despite being treated with RAS inhibitors \[[@gfy154-B42]\]. Various measurements of albuminuria (e.g. ACR, protein:creatinine ratio and urine dipstick) are even harder to standardize, with qualitative measurement using dipstick having the lowest accuracy \[[@gfy154-B44]\].

Autonomic dysfunction, such as prolonged QT interval, is a strong prognostic predictor in T2D. One in two to four affected individuals might die within 5--10 years of diagnosis compared with those without \[[@gfy154-B45]\]. Glucotoxicity-mediated pathological processes, for example, accumulation of advanced glycosylation end-products, increased oxidative stress, activation of protein kinase C and polyol pathways, can cause direct neuronal injury, chronic endoneural ischaemia and nerve hypoxia \[[@gfy154-B32], [@gfy154-B45]\]. Patients with diabetic peripheral neuropathy had small sweat glands with reduced ductal diameter. This was attributable to abnormal thickening of the capillary endothelium causing damage to cutaneous microvasculatures \[[@gfy154-B11]\]. Autonomic neuropathy involving cardiovascular and sudomotor functions affects 60% of people with CKD \[[@gfy154-B46]\]. Neurovascular damage shares common risk factors and frequently coexist. Given its confirmed utility in predicting autonomic and sensory neuropathy, the predictive value of the ESC composite score in detecting incident cardiovascular--renal events and all-cause death, via indirect assessment of sudomotor function, is biologically plausible. This proposition is supported by consistent results from our case--control \[[@gfy154-B18]\], cross-sectional \[[@gfy154-B15]\] and prospective analysis, although these results will need to be replicated in other populations.

This is the first report indicating the feasibility of using a point-of-care tool to detect individuals with T2D and preserved renal function who were at high risk of developing cardiovascular--renal events and all-cause death after 2 years. In this prospective analysis, we confirmed the preferred use of the Chinese-specific threshold of the ESC composite score (≤53) to detect incident CKD compared with other ethnic-specific thresholds derived from cross-sectional studies such as an ESC composite score \<59.5 for mainland Chinese or a mean feet ESC measurement of 37.6--44.4 for African Americans and European Americans \[[@gfy154-B13], [@gfy154-B17], [@gfy154-B18]\]. Given the detailed data management of the JADE register, we were able to examine the effects of various cardiometabolic risk factors, comorbidities and medication use on the ESC composite score to confirm its independent utility.

Regarding the limitations, the definition of CKD in our study was based on reduced eGFR derived from serum creatinine. Despite the potential confounding effects of drug treatment and the wide intra-individual variability of albuminuria, our results remained robust after adjustment in our multivariable analyses. The results of incident CVD and all-cause death should be interpreted with caution given the relatively low event rates, short duration of follow-up and wide 95% CIs when stratified by different thresholds of the ESC composite score, eGFR category and albuminuria status. Longitudinal studies are required to validate and evaluate the significance of other subscores. Although sudomotor assessment holds promise in promoting CKD screening and detection in our cohort, urinary albumin and GFR assessments remain the gold standard in the diagnosis and management of CKD.

Given its simple-to-use and non-invasive nature with reliable repeat measurements, SUDOSCAN can be part of opportunistic CKD surveillance programmes in routine primary care services, especially in low-resource settings. In line with the International Society of Nephrology Closing the Gaps CKD Initiative, increasing accessibility to accurate point-of-care testing, for example, SUDOSCAN, can facilitate care prioritization and informed decision making to facilitate early diagnosis and management \[[@gfy154-B44]\]. However, the optimal thresholds of the ESC composite score will need to be determined in a more diverse population taking ethnicity into consideration. In sum, a low ESC composite score is a useful risk prediction marker for cardiovascular--renal events and all-cause death in the Chinese population with T2D. By distinguishing the high-risk from the low-risk group, use of the ESC composite score may select patients for definitive evaluation and intensive management, although formal cost-effectiveness analysis is needed to quantify these benefits.
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